{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:28:33Z","timestamp":1790731713100,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GE2519\/8-1"],"award-info":[{"award-number":["GE2519\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GE2519\/9-1"],"award-info":[{"award-number":["GE2519\/9-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DU548\/9-1 515982377"],"award-info":[{"award-number":["DU548\/9-1 515982377"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017694","name":"Hermann and Lilly Schilling Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xcrm.2024.101794","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:36:43Z","timestamp":1729679803000},"page":"101794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-3759","authenticated-orcid":false,"given":"Jonathan","family":"Wickel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sayer-Klink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Rinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Borie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dudziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-581X","authenticated-orcid":false,"given":"Christian","family":"Geis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101794_bib1","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"187","author":"Lambert","year":"1956","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.xcrm.2024.101794_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1212\/WNL.0000000000001225","article-title":"Lambert-Eaton syndrome IgG inhibits transmitter release via P\/Q Ca2+ channels","volume":"84","author":"Spillane","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2024.101794_bib4","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.95.14.8328","article-title":"Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons","volume":"95","author":"Pinto","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101794_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410420204","article-title":"Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse","volume":"42","author":"Waterman","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2024.101794_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CND.0000000000000239","article-title":"Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS","volume":"20","author":"Shieh","year":"2019","journal-title":"J.\u00a0Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40120-022-00354-8","article-title":"The European Lambert-Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment","volume":"11","author":"Meisel","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.xcrm.2024.101794_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.xcrm.2024.101794_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.xcrm.2024.101794_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T\u00a0cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2024.101794_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2024.101794_bib12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.xcrm.2024.101794_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s13063-020-04516-7","article-title":"Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis","volume":"21","author":"Wickel","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.xcrm.2024.101794_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2024.101794_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2024.101794_bib16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T\u00a0cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.xcrm.2024.101794_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.xcrm.2024.101794_bib18","first-page":"4655","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.xcrm.2024.101794_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2024.101794_bib20","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T\u00a0cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101794_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T\u00a0cell therapy for autoimmune disease","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101794_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T\u00a0cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.xcrm.2024.101794_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T\u00a0cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","author":"Haghikia","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib25","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2022-eular.1120","article-title":"OP0279 CAR-T cell treatment of refractory systemic lupus erythematosus- safety and preliminary efficacy data from the first four patients","volume":"81","author":"Schett","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T\u00a0cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T\u00a0cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101794_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T\u00a0cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101794_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101794_bib31","doi-asserted-by":"crossref","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T Cell Performance: How to Improve Their Persistence?","volume":"13","author":"Lopez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101794_bib32","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101794_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101794_bib34","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2024.101794_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib36","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101794_bib37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101794_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/ard.2005.044487","article-title":"Repeated B cell depletion in treatment of refractory systemic lupus erythematosus","volume":"65","author":"Ng","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101794_bib41","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.xcrm.2024.101794_bib42","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101794_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101794_bib44","first-page":"1978","article-title":"Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome","volume":"22","author":"Nicolle","year":"2016","journal-title":"Continuum Soc. Soc. Work. Leadersh. Health. Care."},{"key":"10.1016\/j.xcrm.2024.101794_bib45","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2024.101794_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","article-title":"The European LEMS Registry: Baseline Demographics and Treatment Approaches","volume":"4","author":"Mantegazza","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.xcrm.2024.101794_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib48","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101794_bib49","doi-asserted-by":"crossref","first-page":"e008975","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101794_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101794_bib51","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2024.101794_bib52","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101794_bib53","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci. Adv."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912400541X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912400541X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:16:42Z","timestamp":1778919402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912400541X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S266637912400541X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101794","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101794"}}